Walleye Capital LLC trimmed its position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) by 32.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,000 shares of the company’s stock after selling 8,196 shares during the period. Walleye Capital LLC’s holdings in Edgewise Therapeutics were worth $135,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Amalgamated Bank acquired a new stake in Edgewise Therapeutics during the first quarter worth about $61,000. SG Americas Securities LLC bought a new position in shares of Edgewise Therapeutics in the second quarter worth about $90,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Edgewise Therapeutics in the second quarter worth about $96,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Edgewise Therapeutics in the first quarter worth about $125,000. Finally, State Board of Administration of Florida Retirement System bought a new position in shares of Edgewise Therapeutics in the second quarter worth about $175,000.
Analyst Ratings Changes
A number of research firms have recently commented on EWTX. Royal Bank of Canada dropped their target price on shares of Edgewise Therapeutics from $31.00 to $29.00 and set an “outperform” rating for the company in a report on Friday, November 4th. The Goldman Sachs Group cut shares of Edgewise Therapeutics from a “neutral” rating to a “sell” rating and set a $5.00 target price for the company. in a report on Wednesday, August 24th.
Insider Activity at Edgewise Therapeutics
Edgewise Therapeutics Price Performance
Shares of NASDAQ EWTX opened at $10.00 on Monday. The company has a 50 day simple moving average of $9.94 and a 200 day simple moving average of $9.14. The firm has a market cap of $632.14 million, a PE ratio of -8.20 and a beta of -0.23. Edgewise Therapeutics, Inc. has a 1 year low of $5.41 and a 1 year high of $22.98.
Edgewise Therapeutics Profile
Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.
- Get a free copy of the StockNews.com research report on Edgewise Therapeutics (EWTX)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.